geldanamycin

Geldanamycin, an HSP90 inhibitor (Kd: 1.2 μM), specifically disrupts glucocorticoid receptor (GR)/HSP association.

Aminohexylgeldanamycin (AHGDM), a derivative of Geldanamycin, is a highly effective inhibitor of HSP90. It exhibits considerable antiangiogenic and antitumor properties[1].

Aminohexylgeldanamycin (AHGDM) hydrochloride is a Geldanamycin derivative and a powerful inhibitor of HSP90. It exhibits significant antiangiogenic and antitumor properties.

17-O-Demethylgeldanamycin is a secondary metabolite that can be isolated from Streptomyces. It exhibits cytotoxic effects against various tumor cells, demonstrating antitumor activity.

IPI-493 (17-amino17demethoxy) is a novel HSP90 inhibitor with antitumor activity.

2-Methoxyhydroquinone inhibits MAO-A and MAO-B and reduces TNF-α-induced CCL2 production, often serving as a precursor for synthesising the Hsp90 inhibitor Geldanamycin.

17-DMAP-GA, a Geldanamycin analogue, acts as an HSP90 inhibitor, leading to cell cycle abnormalities.

Anticancer agent 136 (compound 22), a C17-triazole analogue of Geldanamycin (GDM), exhibits an IC50 value of 3.38 μM against human dermal fibroblasts (HDF) and binds to Heat shock protein 90 (Hsp90) with a dissociation constant (Kd) of 3.86 μM, demonstrating its apoptosis-inducing capabilities [1].